New small molecules for the treatment of Parkinson's disease

An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers

(2010) David J. Brooks et al.   CLINICAL NEUROPHARMACOLOGY

Gene Therapy in Parkinsonʼs Disease

(2010) Li Rebekah Feng et al.   CNS DRUGS

Gene therapy in hemiparkinsonian rhesus monkeys: long-term survival and behavioral recovery by transplantation of autologous human tyrosine hydroxylase-expressing neural stem cells

(2010) Qiang Xu et al.   CYTOTHERAPY

Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

(2010) T. H. Johnston et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease

(2010) Juliana Bronzova et al.   MOVEMENT DISORDERS

Examining Braak's hypothesis by imaging Parkinson's disease

(2010) David J. Brooks   MOVEMENT DISORDERS

Gene therapy for Parkinson's disease

(2010) Tomas Bjorklund et al.   MOVEMENT DISORDERS

Unilateral pedunculopontine stimulation improves falls in Parkinson's disease

(2009) E. Moro et al.   BRAIN

Gene Therapy for Neurological Disorders: Challenges and Future Prospects for the Use of Growth Factors for the Treatment of Parkinsons Disease

(2009) Fredric Manfredsson et al.   CURRENT GENE THERAPY

Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients with Advanced Parkinson’s Disease

(2009) R.A. Hauser et al.   EUROPEAN NEUROLOGY

The α2adrenoceptor antagonist idazoxan alleviates l-DOPA-induced dyskinesia by reduction of striatal dopamine levels: anin vivomicrodialysis study in 6-hydroxydopamine-lesioned rats

(2009) Kerstin Buck et al.   JOURNAL OF NEUROCHEMISTRY

Pathologic findings in retinal pigment epithelial cell implantation for Parkinson disease

(2009) E. S. Farag et al.   NEUROLOGY

Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats

(2009) N. Yamamoto et al.   NEUROSCIENCE

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

(2009) C. Warren Olanow et al.   NEW ENGLAND JOURNAL OF MEDICINE

P1.203 Immediate vs. delayed-start pramipexole in early Parkinson's disease: the PROUD study

(2009) A. Schapira et al.   PARKINSONISM & RELATED DISORDERS

What do clinical trials tell us about treating patients?

(2009) William J. Weiner   PARKINSONISM & RELATED DISORDERS

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys

(2009) Laurent Grégoire et al.   PARKINSONISM & RELATED DISORDERS

Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment

(2009) Marco Onofrj et al.   PARKINSONISM & RELATED DISORDERS

Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial

(2009) H.H. Fernandez et al.   PARKINSONISM & RELATED DISORDERS

Viral vectors for neurotrophic factor delivery: A gene therapy approach for neurodegenerative diseases of the CNS

(2009) Seung T. Lim et al.   PHARMACOLOGICAL RESEARCH

The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys

(2009) Cindy Achat-Mendes et al.   PSYCHOPHARMACOLOGY

Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?

(2008) Joseph Jankovic   ANNALS OF NEUROLOGY

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

There Is No Parkinson Disease

(2008) William J. Weiner   ARCHIVES OF NEUROLOGY

Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

(2008) Atheir Abbas et al.   EXPERT OPINION ON PHARMACOTHERAPY

Role of homocysteine in the treatment of Parkinson's disease

(2008) Thomas Müller   Expert Review of Neurotherapeutics

Placebo influences on dyskinesia in Parkinson's disease

(2008) Christopher G. Goetz et al.   MOVEMENT DISORDERS

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

(2008) Robert A. Hauser et al.   MOVEMENT DISORDERS

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

(2008) M. Stacy et al.   NEUROLOGY

Spheramine for treatment of Parkinson’s disease

(2008) Natividad P. Stover et al.   Neurotherapeutics